Femasys (NASDAQ:FEMY) Lowered to “Sell” Rating by Wall Street Zen

Femasys (NASDAQ:FEMY) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

A number of other analysts also recently commented on FEMY. Weiss Ratings reiterated a “sell (e+)” rating on shares of Femasys in a research report on Thursday, January 22nd. Lake Street Capital initiated coverage on Femasys in a research note on Tuesday, March 3rd. They set a “buy” rating and a $1.50 price target for the company. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Femasys currently has a consensus rating of “Moderate Buy” and an average price target of $5.50.

Femasys Stock Performance

FEMY opened at $0.48 on Friday. Femasys has a 1-year low of $0.31 and a 1-year high of $1.39. The stock has a market cap of $28.21 million, a P/E ratio of -0.67 and a beta of -2.53. The stock’s 50 day simple moving average is $0.55 and its 200 day simple moving average is $0.63. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.16 and a quick ratio of 0.61.

Institutional Investors Weigh In On Femasys

A number of large investors have recently bought and sold shares of the stock. Kovack Advisors Inc. purchased a new position in Femasys during the fourth quarter worth $27,000. Osaic Holdings Inc. purchased a new stake in shares of Femasys in the second quarter valued at $45,000. HRT Financial LP purchased a new stake in shares of Femasys in the fourth quarter valued at $30,000. Cetera Investment Advisers acquired a new stake in shares of Femasys during the fourth quarter valued at $36,000. Finally, State Street Corp boosted its stake in shares of Femasys by 43.5% during the fourth quarter. State Street Corp now owns 80,869 shares of the company’s stock valued at $47,000 after acquiring an additional 24,500 shares during the last quarter. Institutional investors and hedge funds own 65.27% of the company’s stock.

Femasys Company Profile

Femasys International, Inc is a medical device company focused on the research, development and commercialization of innovative technologies for interventional women’s health applications. The company’s core activities center on creating minimally invasive diagnostic and therapeutic products designed to address uterine cavity evaluation and treatment and to improve outcomes in gynecological care.

The company’s flagship product, the FemVue® hydrosonography system, is a single-use catheter-based device that enhances visualization of the uterine cavity through saline infusion sonography.